enca - 22 days ago

Pfizer completes Metsera acquisition in deal worth up to $10 bn Estelle.Bronkhorst Fri, 11/14/2025 - 09:00 NEW YORK - US drugmaker Pfizer said that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10-billion after a fierce bidding war.The approval from Metsera s shareholders opens the door for Pfizer to make inroads into the fast-growing market for weight loss drugs.Metsera, a US company specialising in obesity treatments, had been the subject of escalating offers from Pfizer and Danish challenger Novo Nordisk, which makes the weight loss drug Wegovy and Ozempic, a diabetes medication with weight loss benefits.Pfizer said in a statement that its acquisition was successfully completed.It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10-billion.This involved $65.60 per share in cash, and an additional $20.65 per share linked to the success of its drug pipeline. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it, said Pfizer chief executive Albert Bourla. We look forward to combining Metsera s innovative portfolio with our global development, manufacturing and commercial infrastructure, he added.The potential sale of Metsera to Novo Nordisk had drawn scrutiny over potential antitrust implications.

Latest News

Hashtags:   

Pfizer

 | 

completes

 | 

Metsera

 | 

acquisition

 | 

worth

 | 

Sources